@Article{biocell.2019.06111,
AUTHOR = {Nesrine EBRAHIM, Eman EHSAN, Eman Abd EL GHANY, Dina SABRY, Ashraf SHAMAA},
TITLE = {Mesenchymal stem cells transplantation attenuates experimentally induced brain injury after neonatal hypoxia by different two routes of administrations},
JOURNAL = {BIOCELL},
VOLUME = {43},
YEAR = {2019},
NUMBER = {1},
PAGES = {21--28},
URL = {http://www.techscience.com/biocell/v43n1/33354},
ISSN = {1667-5746},
ABSTRACT = { The neonatal hypoxic–ischemic encephalopathy (HIE) is an important cause of neurological morbidity and
mortality in neonates. Cell therapy is considered a promising method for treating severe neurological disorders such as
this one. Stem cells have the capacity for self-renewal and differentiation into certain cell lineages. The present study was
aimed to find out the most beneficial route of bone marrow-derived mesenchymal stem cells (BMSCs) administration
for the attenuation of experimentally induced HIE in neonatal rats. Sixty neonatal rats were divided randomly into
four groups. Group 1: control group. Group 2: rats were exposed to bilateral ligation of cephalic arteries. Group 3: rats
were exposed to bilateral ligation of cephalic arteries and then underwent intravenous (IV) BMSC injection. Group 4:
rats were exposed to bilateral ligation of cephalic arteries and then underwent intracerebroventricular (ICV) BMSC
injection. The animals were evaluated by (a) neurobehavioral tests; (b) histopathology, i.e., histological and immunohistochemical studies; and (3) gene expression studies. The BMSC treated groups (3 and 4) showed improvement in
neurobehavioral tests, histopathological studies, and gene expression, as compared to non-injected lesioned rats (Group
2) with better improvement in Group 4 (ICV injections) than in Group 3 (IV injections).},
DOI = {10.32604/biocell.2019.06111}
}